Further investigation revealed that RALYL, a modifier expressed explicitly in malignant cells, may be crucial in driving DMG progression and regulating alternative splicing events, offering a potential therapeutic target for this aggressive glioma subtype. This evidence concerns the gene RALYL and central nervous system cancer.